Nuvectis Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Nuvectis Pharma, Inc. (NVCT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are NVCT insiders buying or selling?
In the last 12 months, Nuvectis Pharma, Inc. insiders reported 6 open-market purchases ($2.3M) and 0 sales ($0) — net buying of $2.3M. Since February 2022, Trabud has recorded 93 Form 4 filings for NVCT: 92 buys ($10.9M) and 1 sells ($22.5K).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $957.1K by Mosseri Marlio Charles (10% Owner) on Oct 29, 2025. SEC ↗
- The most recent open-market purchase was reported on Jul 1, 2026 (3 months ago).
Key Statistics (February 2022 – Jul 1, 2026)
Total Form 4 filings
93
SEC EDGAR
Insider filers
8
Insider buys (92)
$10.9M
Insider sells (1)
$22.5K
Insider sentiment
Net buyingNet insider flow of $10.8M in net buying since February 2022, and $2.3M in net buying over the last 12 months.
Recent NVCT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Mosseri Marlio Charles | 10% Owner | Purchase | 50.0K | $18.32 | $916.0K | SEC ↗ |
| Jul 1, 2026 | Ron Bentsur | Chairman & CEO | Purchase | 12.5K | $20.00 | $250.0K | SEC ↗ |
| Nov 6, 2025 | Ron Bentsur | Chairman & CEO | Purchase | 5.0K | $5.72 | $28.6K | SEC ↗ |
| Nov 6, 2025 | Juan Sanchez | Director | Purchase | 13.0K | $5.79 | $75.3K | SEC ↗ |
| Nov 6, 2025 | Matthew L. Kaplan | Director | Purchase | 11.0K | $5.84 | $64.2K | SEC ↗ |
| Oct 29, 2025 | Mosseri Marlio Charles | 10% Owner | Purchase | 154.8K | $6.18 | $957.1K | SEC ↗ |
| Jun 24, 2025 | Mosseri Marlio Charles | 10% Owner | Purchase | 5.6K | $7.99 | $44.8K | SEC ↗ |
| Jun 20, 2025 | Mosseri Marlio Charles | 10% Owner | Purchase | 33.4K | $8.06 | $269.5K | SEC ↗ |
| May 13, 2025 | Mosseri Marlio Charles | 10% Owner | Purchase | 21.2K | $8.11 | $171.7K | SEC ↗ |
| May 12, 2025 | Mosseri Marlio Charles | 10% Owner | Purchase | 27.7K | $8.94 | $247.3K | SEC ↗ |
| May 9, 2025 | Mosseri Marlio Charles | 10% Owner | Purchase | 27.4K | $8.60 | $235.6K | SEC ↗ |
| Feb 11, 2025 | Mosseri Marlio Charles | 10% Owner | Purchase | 240.0K | $5.00 | $1.2M | SEC ↗ |
| Dec 26, 2024 | Ron Bentsur | Chairman & CEO | Purchase | 4.5K | $4.65 | $20.9K | SEC ↗ |
| Dec 16, 2024 | Mosseri Marlio Charles | 10% Owner | Purchase | 49.1K | $4.66 | $228.9K | SEC ↗ |
| Dec 16, 2024 | Mosseri Marlio Charles | 10% Owner | Purchase | 17.0K | $4.70 | $79.9K | SEC ↗ |
| Nov 20, 2024 | Poradosu Enrique | Chief Science & Business Off | Purchase | 2.0K | $4.99 | $10.0K | SEC ↗ |
| Nov 18, 2024 | Ron Bentsur | Chairman & CEO | Purchase | 20.0K | $4.92 | $98.4K | SEC ↗ |
| Nov 8, 2024 | Michael J. Carson | Vice President, Finance | Sale | 2.8K | $8.16 | $22.5K | SEC ↗ |
| May 15, 2024 | Ron Bentsur | Chairman & CEO | Purchase | 1.9K | $6.74 | $13.1K | SEC ↗ |
| May 13, 2024 | Ron Bentsur | Chairman & CEO | Purchase | 2.0K | $6.40 | $12.8K | SEC ↗ |
| May 13, 2024 | Poradosu Enrique | Chief Science & Business Off | Purchase | 500 | $6.29 | $3.1K | SEC ↗ |
| May 13, 2024 | Shemesh Shay | Chief Dev. & Ops. Officer | Purchase | 1.1K | $6.32 | $7.0K | SEC ↗ |
| Oct 12, 2023 | Ron Bentsur | Chairman & CEO | Purchase | 640 | $11.08 | $7.1K | SEC ↗ |
| Oct 10, 2023 | Ron Bentsur | Chairman & CEO | Purchase | 1.1K | $11.21 | $12.1K | SEC ↗ |
| Oct 6, 2023 | Ron Bentsur | Chairman & CEO | Purchase | 3.2K | $11.01 | $35.5K | SEC ↗ |
Showing the 25 most recent of 93 Form 4 filings for Nuvectis Pharma, Inc..
Most active NVCT insiders
- Ron Bentsur45 filings
- Mosseri Marlio Charles26 filings
- Shemesh Shay12 filings
- Poradosu Enrique5 filings
- Matthew L. Kaplan2 filings
Ask anything about NVCT insider activity
Use Trabud's AI agent to query Nuvectis Pharma, Inc.'s Form 4 history in plain English — "Show me NVCT CEO purchases this year" or compare it against any other ticker.
Open the AI agentNVCT insider trading FAQ
Are Nuvectis Pharma, Inc. insiders buying or selling?
In the last 12 months, Nuvectis Pharma, Inc. insiders reported 6 open-market purchases ($2.3M) and 0 sales ($0) — net buying of $2.3M. Since February 2022, Trabud has recorded 93 Form 4 filings for NVCT: 92 buys ($10.9M) and 1 sells ($22.5K). Over the full record that is net buying of $10.8M.
How many insiders trade NVCT stock?
8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Nuvectis Pharma, Inc.. The most recent filing was accepted on Jul 1, 2026.
Where does Trabud get NVCT insider trading data?
All NVCT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.